Medical Advocates

Nevirapine
(Viramune)
 
Journal Citations:  Adolescent/Adult Indications
 
General Reports
NVP/3TC 

NVP/EFV/DDI 
NVP/Etravirine
NVP/TNF/E
MT
NVP/STV/3TC
NVP/ZDV/DDI vs STV/DDI
NVP/ZDV/3TC
STV/DDI/NVP
Miscellaneous  Combinations
Post-Exposure Prophylaxis
Dosing
Adherence
Treatment Strategies

 



 

NVP Main Page Journal Main Page Main New/Newsworthy  Home Page

Last Update:  October 01, 2016
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

General Reports
           

 
Lipid-based nutrient supplements do not affect efavirenz but lower plasma nevirapine concentrations in Ethiopian adult HIV patients.
Abdissa A, Olsen MF, Yilma D, et al
HIV Med
. 2015 May 13.
Abstract  

FULL-TEXT ARTICLE
Cytochrome P450 2B6 genetic variants are associated with plasma nevirapine levels and clinical response in HIV-1 infected Kenyan women: a prospective cohort study.
Oluka MN, Okalebo FA, Guantai AN, et al
AIDS Res Ther
. 2015 Apr 15;12:10.
Paper

FULL-TEXT ARTICLE
Nevirapine-Based Regimens in HIV-Infected Antiretroviral-Naive Patients: Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Kawalec P, Kryst J, Mikrut A, Pilc A.  
PLoS One
. 2013 Oct 7;8(10):e76587.
Paper

FULL-TEXT PDF ARTICLE(pdf of article must be downloaded from the publication website)
Differential responses of human hepatocytes to the non-nucleoside HIV-1 reverse transcriptase inhibitor nevirapine.
Fang JL, Beland FA.
J Toxicol Sc
i
. 2013;38(5):741-52
"
P
aper

Long-Term Benefits of Nevirapine-Containing Regimens: Multicenter Study with 506 Patients,
Followed-Up a Median of 9 Years.
Podzamczer D, Tiraboschi JM, Mallolas J, et al
Curr HIV Res. 2012 Jun 21.
Abstract  

Comparative durability of nevirapine versus efavirenz in first-line regimens during the first year of initiating antiretroviral therapy among Swaziland HIV-infected adults.
Takuva S, Evans D, Zuma K, Okello V, Louwagie G.
Pan Afr Med J
. 2013 May 3;15:5

Abstract

The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study.
The HIV-CAUSAL Collaboration.
AIDS
.
2012 Apr 26.
Abstract


A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-na´ve patients.
Dejesus E, Mills A, Bhatti L, et al
Int J Clin Pract
. 2011 Oct 14.
Abstract

Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-na´ve HIV-1-infected patients (the ARTEN study).
Podzamczer D, Andrade-Villanueva J, Clotet B,  et al
HIV Med
. 2011 Apr 24.
Abstract

Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml.
Ha´m-Boukobza S, Morand-Joubert L, Flandre P,  et al
AIDS
. 2010 Dec 13
.
Abstract

Protein Adducts As Prospective Biomarkers of Nevirapine Toxicity.
Antunes AM, Godinho AL, Martins IL, et al
Chem Res Toxicol
. 2010 Sep 1
Abstract

Long-Term Effectiveness and Safety Outcomes in HIV-1-Infected Patients After a Median Time of 6 Years on Nevirapine.
RodrÝguez-Arrondo F, Aguirrebengoa K, Portu J, et al
Curr HIV Res. 2009 Sep;7(5):526-532
Abstract

Pharmacokinetics of Nevirapine and Lamivudine in Patients with HIV-1 Infection.
Sabo J, Lamson M, Leitz G, et al  
AAPS PharmSci 2000;2(1):E1
Abstract

 

NVP/3TC
           

  Pharmacokinetics of Nevirapine and Lamivudine in Patients with HIV-1 Infection.
Sabo J, Lamson M, Leitz G, et al  
AAPS PharmSci 2000;2(1):E1
Abstract
 

NVP/3TC
           

  Pharmacokinetics of Nevirapine and Lamivudine in Patients with HIV-1 Infection.
Sabo J, Lamson M, Leitz G, et al  
AAPS PharmSci 2000;2(1):E1
Abstract
 

NVP/EFV/DDI
           

  Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily
regimen for patients with HIV infection.
Jordan WC, Jefferson R, Yemofio F, et al
J Natl Med Assoc. 2003 Dec; 95(12): 1152-7.
Abstract

NVP/Etravirine
           

  Susceptibility to Etravirine of HIV-1 subtype C isolates from Nevirapine/Efavirenz-experienced patients: comparative interpretation of ANRS and STANFORD algorithms.
Fleury HJ, Anquetil D, Deshpande A, et al 
AIDS Res Hum Retroviruses. 2012 Apr 20.

Abstract

NVP/TNF/EMT
           

  FULL-TEXT ARTICLE
Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia.
Llibre JM, Bravo I, Ornelas A, et al
PLoS One
. 2015 Jun 24;10(6):e0128131.
Paper

Evaluation of the Safety and Effectiveness of Nevirapine Plus Coformulated Tenofovir/Emtricitabine as First-Line Therapy in Routine Clinical Practice.
Vallecillo G, Domingo P, Mallolas J,  et al
AIDS Res Hum Retroviruses
. 2011 Jul 26
Abstract


NVP/STV/3TC
           

 
Management of HIV-1 Infection With a Combination of Nevirapine, Stavudine, and Lamivudine: A Preliminary Report on the Nigerian Antiretroviral Program.
Idigbe EO, Adewole TA, Eisen G, et al  
J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):65-69.
Abstract
 
FULL-TEXT ARTICLE
Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral-Therapy-Naive Patients Infected with HIV-1
van Leth F , Phanuphak P Stroes  E , et al  
PLoS Medicine
Vol 1, No 1
Paper

FULL-TEXT PDF ARTICLE
Effectiveness and tolerability of nevirapine, stavudine, and lamivudine in clinical practice.
Yozviak JL, Eric Doerfler R, Woodward WC.
HIV Clin Trials 2001 Nov-Dec;2(6):474-476
PDF Paper

Nevirapine or Efavirenz Combined with Two Nucleoside Reverse Transcriptase Inhibitors Compared to HAART: A Meta-Analysis of Randomized Clinical Trials.
Torre D, Tambini R, Speranza F, et al
HIV Clin Trials 2001 Mar-Apr;2(2):113-21
Abstract

Efficacy of nevirapine-based haart in hiv-1-infected, treatment-naive persons with high and low baseline viral loads
Raffi F, Reliquet V, Podzamczer D, Pollard RB.
 H
IV Clin Trials 2001 Jul-Aug;2(4):317-22
Abstract

 

NVP/ZDV/DDI vs ZDV/DDI
           

  Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial.
NIAID Clinical Trials Group Protocol 241 Investigators.
D'Aquila RT, Hughes MD, Johnson VA, et al.
Ann Intern Med 1996 Jun 15;124(12):1019-30

Abstract 
 

NVP/ZDV/3TC
           

  Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
Munderi P, Walker AS, Kityo C,  et al
HIV Med. 2010 Feb

Abstract 
 

STV/DDI/NVP
           

  Immunologic response to antiretroviral treatment with combined stavudine, didanosine and nevirapine.
Reliquet V, Robillard N, Perre P, et al
Presse Med 2001 Jul 7-3;30(23):1143-7
Abstract
 

Miscellaneous Combinations
           

 
Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects.
Smith DE, Chan DJ, Maruszak H, Jeganathan S.
Int J STD AIDS. 2011 Apr;22(4):228-30
Abstract

Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-na´ve individuals.
Mbuagbaw LC, Irlam JH, Spaulding A,  et al
Cochrane Database Syst Rev
. 2010 Dec 8;12:CD004246.
Abstract

Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting.
Kiertiburanakul S, Wiboonchutikul S, Sukasem C,  et al 
J Clin Virol
. 2010 Feb 24
Abstract

 

Post-Exposure Prophylaxis
       

 
Tolerance of a Short Course of Nevirapine, Associated With 2 Nucleoside Analogues, in Postexposure Prophylaxis of HIV.
Rey D, Partisani M, Hess-Kempf G, et al 

J Acquir Immune Defic Syndr. 2004 Dec 1;37(4):1454-6.
Abstract

Drug-induced aminotransferase alterations during antiretroviral HIV post-exposure prophylaxis.
Puro V, Soldani F, De Carli G, et al 

AIDS.
2003 Sep 5;17(13):1988-90
.
Abstract


Dosing
       

 
Finding of nevirapine extended release tablet remnants in stools does not threaten the success of combination antiretroviral therapy
Stephan C, Leˇn W.
HIV Med
. 2013 Sep 23.

Abstract

Considerations on the New Nevirapine: Switching Patients from Twice-Daily to Once-Daily.
Ward D, Slim J.  
J Int Assoc Physicians AIDS Care
(Chic)
. 2013 Feb 28
Abstract

Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment.
Yone EW, Kengne AP.
HIV AIDS
(Auckl)
. 2012;4:181-4.
Abstract


Safety and efficacy of once-daily nevirapine dosing: a multicohort study.
Calmy A, Vallier N, Nguyen A, Lange JM,  et al
Antivir Ther
. 2009;14(7):931-938.
Abstract

Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach.
Moltˇ J, Valle M, Miranda C ,et al
J Antimicrob Chemother. 2008 Jun 30.
Abstract
 

Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review.
Cooper C, van Heeswijk R.
HIV Med. 2007 Jan;8(1):1-7.

Abstract

Adherence
       

 
Home deliveries: Implications for adherence to nevirapine in a PMTCT programme in rural Malawi.
Kasenga F, Hurtig AK, Emmelin M.
AIDS Care. 2007 May;19(5):646-52.

Abstract

 


NVP  Main Page Journal Main Page Main New/Newsworthy  Home Page

Nevirapine Journal Data
Adolescent/Adult Indications